Cargando…

Differences in Whole-Blood Transcriptional Profiles in Inflammatory Bowel Disease Patients Responding to Vedolizumab Compared with Non-Responders †

Vedolizumab is efficacious in the treatment of Crohn’s disease (CD) and ulcerative colitis (UC). However, a significant proportion of patients present with a non-response. To investigate whether differences in the clinical response to vedolizumab is reflected in changes in gene expression levels in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haglund, Sofie, Söderman, Jan, Almer, Sven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052064/ https://www.ncbi.nlm.nih.gov/pubmed/36982892 http://dx.doi.org/10.3390/ijms24065820

Ejemplares similares

Gene Expression and Thiopurine Metabolite Profiling in Inflammatory Bowel Disease – Novel Clues to Drug Targets and Disease Mechanisms?
por: Haglund, Sofie, et al.
Publicado: (2013)

Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease
por: Salvador-Martín, Sara, et al.
Publicado: (2021)

Combination treatment with 6-mercaptopurine and allopurinol in HepG2 and HEK293 cells – Effects on gene expression levels and thiopurine metabolism
por: Haglund, Sofie, et al.
Publicado: (2017)

Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study
por: Visuri, Isabella, et al.
Publicado: (2023)

Gene Expression-Genotype Analysis Implicates GSDMA, GSDMB, and LRRC3C as Contributors to Inflammatory Bowel Disease Susceptibility
por: Söderman, Jan, et al.
Publicado: (2015)

Genetic variation and expression levels of tight junction genes identifies association between MAGI3 and inflammatory bowel disease
por: Norén, Elisabeth, et al.
Publicado: (2017)

Systemic Chemokine Levels with “Gut-Specific” Vedolizumab in Patients with Inflammatory Bowel Disease—A Pilot Study
por: Zwicker, Stephanie, et al.
Publicado: (2017)

Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study
por: Eriksson, Carl, et al.
Publicado: (2021)

Predicting Response to Vedolizumab in Inflammatory Bowel Disease
por: Meserve, Joseph, et al.
Publicado: (2020)

Management of inflammatory bowel disease in poor responders to infliximab
por: Guerra, Iván, et al.
Publicado: (2014)

Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease
por: Fleisher, Mark, et al.
Publicado: (2018)

Long‐term safety of vedolizumab for inflammatory bowel disease
por: Loftus, Edward V., et al.
Publicado: (2020)

Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms
por: Crooks, Benjamin, et al.
Publicado: (2020)

Effect of obesity on vedolizumab response in inflammatory bowel disease
por: Levine, Louis J., et al.
Publicado: (2022)

Interleukin 34: a new modulator of human and experimental inflammatory bowel disease
por: Zwicker, Stephanie, et al.
Publicado: (2015)

Salivary and Serum Inflammatory Profiles Reflect Different Aspects of Inflammatory Bowel Disease Activity
por: Majster, Mirjam, et al.
Publicado: (2020)

Comparative Transcriptional Analysis of Patient Responders Versus Non-Responders to Glucocorticoid Treatment for Bronchopulmonary Dysplasia
por: Shi, Victoria J, et al.
Publicado: (2021)

Designing biologic selectivity for inflammatory bowel disease – role of vedolizumab
por: Krupka, Niklas, et al.
Publicado: (2014)

A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases
por: Shim, Hang Hock, et al.
Publicado: (2018)

Vedolizumab Is Safe in Elderly Veteran Patients With Inflammatory Bowel Disease
por: Leung, Kenneth, et al.
Publicado: (2021)

Inverse and Concordant Mucosal Pathway Gene Expressions in Inflamed and Non-Inflamed Ulcerative Colitis Patients: Potential Relevance to Aetiology and Pathogenesis
por: Söderman, Jan, et al.
Publicado: (2022)

Effect of Vedolizumab on Anemia of Chronic Disease in Patients with Inflammatory Bowel Diseases
por: Scarozza, Patrizio, et al.
Publicado: (2020)

Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases
por: Lynch, Kate D., et al.
Publicado: (2020)

Use of Vedolizumab in Inflammatory Bowel Disease: A Single-Center Experience
por: Erdoğan, Çağdaş, et al.
Publicado: (2022)

The Role of Vitamin D in Patients with Inflammatory Bowel Disease Treated with Vedolizumab
por: Abraham, Bincy P., et al.
Publicado: (2023)

Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety after the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory Bowel Disease Patients: Single-Center Experience
por: Oršić Frič, Vlasta, et al.
Publicado: (2023)

Comparative Safety of Ustekinumab and Vedolizumab in Older Patients with Inflammatory Bowel Disease: A Bicentric Cohort Study
por: Burgevin, Alice, et al.
Publicado: (2022)

To respond or not to respond: exploring empathy-related psychological and structural brain differences between placebo analgesia responders and non-responders
por: Hartmann, Helena, et al.
Publicado: (2023)

Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases
por: Yarur, Andres J., et al.
Publicado: (2020)

Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: A retrospective cohort study
por: Saad Alshahrani, Abdulaziz, et al.
Publicado: (2023)

Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease
por: Singh, Harmanjit, et al.
Publicado: (2016)

Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases
por: Bertani, Lorenzo, et al.
Publicado: (2020)

Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease
por: Vaughn, Byron P., et al.
Publicado: (2020)

Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases
por: Luzentales-Simpson, Matthew, et al.
Publicado: (2021)

Vedolizumab Immunogenicity With Long‐Term or Interrupted Treatment of Patients With Inflammatory Bowel Disease
por: Wyant, Timothy, et al.
Publicado: (2021)

Efficacy and safety of vedolizumab for pediatrics with inflammatory bowel disease: a systematic review
por: Fang, Shengbo, et al.
Publicado: (2022)

The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea
por: Choi, Myeong Geun, et al.
Publicado: (2022)

The Effect of Vedolizumab on Spondyloarthritis Symptoms in a Cohort of Inflammatory Bowel Disease Patients
por: Huseynzada, Sinakhanım, et al.
Publicado: (2023)

Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease
por: Lutz, Megan, et al.
Publicado: (2023)

Comparative Outcomes and Safety of Vedolizumab vs Tumor Necrosis Factor Antagonists for Older Adults With Inflammatory Bowel Diseases
por: Singh, Siddharth, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_870nfg5gain38adc1ric42u1d3